EA201890878A1 - Способ лечения медуллобластомы с помощью ингибитора ezh2 - Google Patents

Способ лечения медуллобластомы с помощью ингибитора ezh2

Info

Publication number
EA201890878A1
EA201890878A1 EA201890878A EA201890878A EA201890878A1 EA 201890878 A1 EA201890878 A1 EA 201890878A1 EA 201890878 A EA201890878 A EA 201890878A EA 201890878 A EA201890878 A EA 201890878A EA 201890878 A1 EA201890878 A1 EA 201890878A1
Authority
EA
Eurasian Patent Office
Prior art keywords
meddalloblastomes
treatment
ezh2 inhibitor
subject
ezh2
Prior art date
Application number
EA201890878A
Other languages
English (en)
Inventor
Хайке Кайльхак
Найджел Дж. Уотерс
Раджив Вибхакар
Original Assignee
Эпизайм, Инк.
Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпизайм, Инк., Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт filed Critical Эпизайм, Инк.
Publication of EA201890878A1 publication Critical patent/EA201890878A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

В настоящем изобретении предусмотрен способ лечения медуллобластомы у субъекта, нуждающегося в этом, предусматривающий введение субъекту терапевтически эффективного количества ингибитора энхансера гомолога zeste 2 (EZH2). В предпочтительном варианте осуществления данного способа субъект относится к педиатрической группе, и ингибитор EZH2 представляет собой таземетостат.
EA201890878A 2015-10-06 2016-10-05 Способ лечения медуллобластомы с помощью ингибитора ezh2 EA201890878A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562238074P 2015-10-06 2015-10-06
US201662299312P 2016-02-24 2016-02-24
PCT/US2016/055554 WO2017062495A2 (en) 2015-10-06 2016-10-05 Method of treating medulloblastoma with an ezh2 inhibitor

Publications (1)

Publication Number Publication Date
EA201890878A1 true EA201890878A1 (ru) 2018-08-31

Family

ID=58488487

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890878A EA201890878A1 (ru) 2015-10-06 2016-10-05 Способ лечения медуллобластомы с помощью ингибитора ezh2

Country Status (12)

Country Link
US (2) US20190083504A1 (ru)
EP (2) EP3371175A4 (ru)
JP (1) JP7045985B2 (ru)
KR (1) KR20180058829A (ru)
CN (1) CN108699046A (ru)
AU (3) AU2016333982A1 (ru)
CA (1) CA3000983A1 (ru)
EA (1) EA201890878A1 (ru)
IL (2) IL258510A (ru)
MX (1) MX2018004132A (ru)
SG (1) SG10201909413SA (ru)
WO (1) WO2017062495A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
CA3025933A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
US11452727B2 (en) 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
US20220298510A1 (en) * 2019-06-03 2022-09-22 Icahn School Of Medicine At Mount Sinai Compounds and methods for inhibiting cancers via rest inhibition
CN111905102A (zh) * 2020-09-04 2020-11-10 福建医科大学附属第一医院 Ezh2抑制剂在治疗胶质瘤中的应用
KR20230120883A (ko) 2022-02-10 2023-08-17 서울대학교병원 Hsp70을 표적으로 하는 수모세포종 치료 및 전이 억제 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4236945A (en) * 1978-11-27 1980-12-02 Allegheny Ludlum Steel Corporation Phosphorus-iron powder and method of producing soft magnetic material therefrom
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
WO2011140324A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indoles
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
PL2908823T3 (pl) * 2012-10-15 2020-03-31 Epizyme, Inc. Sposoby leczenia nowotworu
ME02730B (me) 2013-02-11 2017-10-20 Constellation Pharmaceuticals Inc Modulatori enzima koji modifikuju metil, njihove kompozicije i upotreba
EP3076977B1 (en) * 2013-12-06 2021-03-03 Epizyme, Inc. Combination therapy for treating cancer
EP3370725A4 (en) * 2015-11-06 2019-07-03 Epizyme, Inc. PEDIATRIC DOSAGE FOR THE TREATMENT OF CANCER WITH AN EZH2 INHIBITOR

Also Published As

Publication number Publication date
SG10201909413SA (en) 2019-11-28
AU2023246384A1 (en) 2023-11-02
CA3000983A1 (en) 2017-04-13
AU2016333982A1 (en) 2018-04-26
JP2018529742A (ja) 2018-10-11
EP3371175A2 (en) 2018-09-12
WO2017062495A2 (en) 2017-04-13
WO2017062495A3 (en) 2017-06-08
IL281318A (en) 2021-04-29
EP3371175A4 (en) 2019-09-25
US20200268765A1 (en) 2020-08-27
IL258510A (en) 2018-05-31
EP4309738A2 (en) 2024-01-24
CN108699046A (zh) 2018-10-23
AU2021204331A1 (en) 2021-07-22
JP7045985B2 (ja) 2022-04-01
MX2018004132A (es) 2018-09-26
US20190083504A1 (en) 2019-03-21
KR20180058829A (ko) 2018-06-01

Similar Documents

Publication Publication Date Title
EA201890878A1 (ru) Способ лечения медуллобластомы с помощью ингибитора ezh2
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
PH12015502075A1 (en) Treatment of cataplexy
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA202091846A1 (ru) Соединения с активностью, индуцирующей ферроптоз, и способы их применения
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201791095A1 (ru) Способ лечения рака
MX2018004043A (es) Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
EA201890801A1 (ru) Способ лечения злокачественной рабдоидной опухоли яичников (mrto)/мелкоклеточного рака яичников гиперкальцемического типа (sccoht) с помощью ингибитора ezh2
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201791907A1 (ru) Бивалентная вакцина против вируса свиного гриппа
EA201792610A1 (ru) Способ лечения неврологического заболевания
MA46459A (fr) Méthode de traitement de lésions rénales aiguës
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
MA51295A (fr) Dosage, procédé et traitement d'alpha-synucléinopathies